Reports - Peptide Synthesis Market
Peptide Synthesis Market Valuation and Growth Forecast 2025-2035 by Product & Service (Reagents, Equipment, Services) by Technology (Solid Phase Peptide Synthesis, Liquid Phase Peptide Synthesis, Hybrid & Recombinant Technology) by End User (Pharmaceutical & Biotechnology Companies, CDMOs & CROs, Academic & Research Institutes) by Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Industry Leaders Trust Us For Actionable Intelligence
USD 649.6 Million
USD 1660.1 Million
8.91%
North America
Asia Pacific
2024
2021 - 2023
2025 - 2035
By Product & Service, By Technology, By End User, By Region
The final deliverable will encompass both quantitative and qualitative data, providing a comprehensive analysis of the market. The scope is customizable.
The global Peptide Synthesis Market is valued at USD 649.6 Million in 2024 and is projected to reach a value of USD 1660.1 Million by 2035 at a CAGR (Compound Annual Growth Rate) of 8.91% between 2025 and 2035.
North America Dominated Sales with a 37.5% share in 2024. The North America region Well-known for its strong healthcare and biotechnology sectors, North America sees substantial demand for peptides in therapeutic applications. The regions advanced research infrastructure and considerable investments in pharmaceutical innovations contribute to its prominent position in the segment. Moreover, strategic collaborations and partnerships within the pharmaceutical industry further enhance North Americas impact on the global peptide synthesis landscape, establishing it as a pivotal hub for advancements and market expansion.
The global Peptide Synthesis market can be categorized as Product & Services, Technology, End User and Region.
| Parameter | Details |
|---|---|
| Segment Covered | By Product & Service
By Technology
By End User
By Region
|
| Companies Covered |
|
| Customization Scope | Enjoy complimentary report customization—equivalent to up to 8 analyst working days—with your purchase. Customizations may include additions or modifications to country, regional, or segment-level data. |
| Pricing and purchase options | Access flexible purchase options tailored to your specific research requirements. Explore purchase options |
In 2024, the reagents category dominated the global peptide synthesis market, constituting the essential chemicals and compounds utilized in peptide synthesis. Based on the Product & Service, the market can be divided into Reagents (Resins, Amino Acids, Coupling Reagents, Dyes and Fluorescent Labeling Reagents, Other Reagents), Equipment (Peptide Synthesizers, Chromatography Equipment, Lyophilizes), and Services. These reagents are crucial to the overall process of peptide production, exerting a notable influence on the efficiency and quality of the synthesized peptides. Both researchers and manufacturers depend on reagents of superior quality to ensure accuracy and consistency in peptide synthesis. Ongoing advancements in reagent technology, including coupling reagents and protecting group chemistry, contribute to improving peptide synthesis methodologies.
In 2024, the liquid phase peptide synthesis (LPPS) segment contributed to the most significant market growth. The Technology segment is divided into Solid Phase Peptide Synthesis, Liquid Phase Peptide Synthesis, and Hybrid & Recombinant Technology. Utilizing liquid-phase techniques, LPPS streamlines the effective formation of peptides by systematically introducing amino acids in a solution. This method presents benefits in terms of purity, output, and scalability. With an increasing demand for peptides in pharmaceutical and biotechnological fields, LPPS becomes prominent due to its capability to generate top-quality peptides while minimizing undesirable side reactions. The segments expansion is additionally driven by advancements in automated synthesis technologies, which augment the pace and accuracy of peptide manufacturing.
In 2024, the pharmaceutical & biotechnology companies segment accounted for over 34.3% market share. The End User segment is categorized into Pharmaceutical & Biotechnology Companies, CDMOs & CROs, and Academic & Research Institutes.These companies are pivotal in driving innovation, research, and development, contributing significantly to the increasing demand for peptides. This segment is a crucial growth driver focusing on developing novel therapeutics and advancing biotechnological solutions.
The market is experiencing major growth due to a sharp increase in the adoption of peptides within the pharmaceutical and consumer healthcare sectors. Peptides find extensive use in addressing various lifestyle disorders like cancers, diabetes, and obesity. The escalating prevalence of these metabolic and lifestyle disorders is creating opportunities for the application of peptide therapeutics in areas such as diabetes, oncology, and metabolic disorders. For instance, the IDF 2021 reveals that 10.5% of the adult population (20-79 years) is afflicted with diabetes, with nearly half unaware of their condition. Moreover, projections from the IDF indicate that by 2045, approximately 783 million adults, or 1 in 8, will be living with diabetes—a 46% increase. The IDF also notes estimates for impaired glucose tolerance (IGT) among those aged 20-79, putting them at a high risk of type 2 diabetes. Peptide therapies, including Glucagon-like peptide-1amide, which stimulates insulin secretion postprandially, are gaining popularity in pancreatic treatment. As a result, the peptide drug market is anticipated to expand alongside the increasing population of individuals with diabetes, fostering market growth throughout the projected period.
Track market trends LIVE & outsmart rivals with our Premium Data Intel Tool : Vantage Point
The surge in demand for therapeutic peptides in the pharmaceutical industry has intensified research and development. Yet, the current peptide synthesis methods involving hazardous coupling agents and solvents pose significant sustainability challenges. The environmental impact of these practices carries economic implications, prompting a crucial shift towards greener synthesis processes. Companies investing in eco-friendly technologies contribute to a positive environmental image and gain a competitive edge in the market, attracting investor interest aligned with the trend of ethical investing. Collaboration on industry standards and meeting consumer preferences for sustainable practices further shape the evolving economic landscape of the peptide synthesis industry, where innovation must intertwine with environmental responsibility for long-term viability.
The competitive landscape of the peptide synthesis industry is characterized by a dynamic market where several significant players exist for prominence. Established companies, such as Bachem, CEM Corporation, Merck KGaA, etc., dominate the industry, leveraging their extensive expertise and technological capabilities. Industry players in Peptide Synthesis are driven by a commitment to advancing technology for innovative solutions that boost efficiency, automation, and high-throughput capabilities. For instance, Biotage has introduced an advanced solution for simultaneous peptide purification, enhancing the automation of the peptide drug discovery process. The newly launched Biotage® PeptiRen-96 well plates, in conjunction with the well-established Biotage® Extrahera™ sample preparation system, facilitate the efficient cleanup of up to 96 peptides concurrently, streamlining the high-throughput workflow.
The key players in the global Peptide Synthesis market include - Merck KGaA among others.
Key features include:
Contact
Toll Free Number+1 (877) 462-2282